HC Wainwright Reiterates “Buy” Rating for Cibus (NASDAQ:CBUS)

Cibus (NASDAQ:CBUS)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 370.81% from the company’s previous close.

CBUS has been the topic of several other reports. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Cibus in a research report on Tuesday, October 22nd. Alliance Global Partners lowered their price target on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group upgraded Cibus to a “strong-buy” rating in a research report on Friday, July 19th.

Cibus Stock Down 7.7 %

Shares of CBUS stock opened at $5.31 on Monday. Cibus has a 12 month low of $2.86 and a 12 month high of $23.18. The firm has a market cap of $122.61 million, a PE ratio of -0.26 and a beta of 1.79. The stock has a 50 day moving average of $4.06 and a 200-day moving average of $8.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Cibus in the 3rd quarter worth approximately $33,000. Charles Schwab Investment Management Inc. grew its position in Cibus by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock valued at $161,000 after acquiring an additional 6,276 shares during the period. FineMark National Bank & Trust raised its stake in Cibus by 24.3% during the second quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after acquiring an additional 4,000 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Cibus during the second quarter worth $214,000. Finally, Rhumbline Advisers bought a new position in shares of Cibus during the second quarter valued at $221,000. Institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.